

Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)

Technology appraisal guidance

Published: 8 August 2024

www.nice.org.uk/guidance/ta994

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma has confirmed that it does not intend to make an evidence submission for the appraisal. Astellas Pharma considers that there is lack of mature overall survival data to provide an evidence submission for this appraisal.

Information

If NHS organisations wish to consider enzalutamide for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6371-3